| Name | Title | Contact Details |
|---|
The Accreditation Council for Graduate Medical Education (ACGME) is a private, non-profit, professional organization responsible for the accreditation of approximately 10,000 residency and fellowship programs and the approximately 800 institutions that sponsor these programs in the United States. Residency and fellowship programs educate approximately 125,000 resident and fellow physicians in 150 specialties and subspecialties. The ACGME`s mission is to improve health care and population health by assessing and advancing the quality of resident physicians` education through accreditation. We imagine a world characterized by: • A structured approach to evaluating the competency of all residents and fellows, • Motivated physician role models leading all graduate medical education programs, • High-quality, supervised, humanistic, clinical educational experience, with customized formative feedback, • Clinical learning environments characterized by excellence in clinical care, safety, and professionalism, • Residents and fellows achieving specialty specific proficiency prior to graduation, • Residents and fellows prepared to become Virtuous Physicians who place the needs and well-being of patients first.
KishHealth System is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. KishHealth System is based in Dekalb, IL. You can find more information on KishHealth System at www.kishhealth.org
Vested Health is a Charleston, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.
eMD Inc. is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.